|1.||Mangin, Pierre H: 1 article (02/2015)|
|2.||Alame, Ghina: 1 article (02/2015)|
|3.||Magnenat, Stéphanie: 1 article (02/2015)|
|4.||Riehl, Nadia: 1 article (02/2015)|
|5.||Freund, Monique: 1 article (02/2015)|
|6.||Petitou, Maurice: 1 article (02/2015)|
|7.||Hechler, Béatrice: 1 article (02/2015)|
|8.||Gachet, Christian: 1 article (02/2015)|
|1.||Atherosclerotic Plaque (Atheroma)
02/01/2015 - "The pharmacological profile of EP217609, its performance in arterial thrombosis models and its possible neutralisation make it an interesting molecule and a potential candidate as an antithrombotic drug. "
02/01/2015 - "EP217609, a neutralisable dual-action FIIa/FXa anticoagulant, with antithrombotic effects in arterial thrombosis."
02/01/2015 - "The effects of EP217609 were compared to those of its parent compounds used alone or in combination in two models of experimental thrombosis induced by FeCl3 injury of the carotid artery or mechanical injury of atherosclerotic plaques in ApoE-deficient mice. "
02/01/2015 - "When administered at low doses increasing the APTT by only 1.1 fold, EP217609 significantly reduced the thrombus area in both models as compared to α-NAPAP analog or fondaparinux alone, but not to the combination of these drugs. "
|1.||Apolipoproteins E (ApoE)
|4.||N(alpha)- (2- naphthylsulfonylglycyl)- 4- amidinophenylalanine piperidide (NAPAP)